Expression of secretory leukocyte protease inhibitor detected by immunohistochemistry correlating with prognosis and metastasis in colorectal cancerReportar como inadecuado




Expression of secretory leukocyte protease inhibitor detected by immunohistochemistry correlating with prognosis and metastasis in colorectal cancer - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

World Journal of Surgical Oncology

, 12:369

First Online: 02 December 2014Received: 02 May 2014Accepted: 18 November 2014

Abstract

BackgroundThe potential of secretory leukocyte protease inhibitor SLPI as a biomarker for colorectal cancer was studied. A prospective, randomized, controlled, clinical trial was conducted in 2013 and 2014 to confirm whether the expression of SLPI correlates with prognosis and metastasis in colorectal cancer patients.

MethodsImmunohistochemistry was used to detect SLPI expression in colorectal cancer. The expression of SLPI was scored by two pathologists independently. Statistical analysis of the data was performed using a Χ test to investigate the influence of SLPI on the pathologic characteristics of colorectal cancer.

ResultsCompared with normal tissue, SLPI was overexpressed in colorectal cancer tissue. Overexpression of SLPI correlated with different grades moderate or good differentiation: 2.7% low expression versus 97.3% high expression, low differentiation: 41.7% low expression versus 58.3% high expression, TNM stage I or II: 4.2% low expression versus 95.8% high expression; III or IV: 19.7% low expression versus 80.3% high expression, lymphatic metastasis 18.6% low expression versus 81.4% high expression and distal metastasis 86.5% low expression versus 13.5% high expression, but not with patient age or sex P = 0.613, P = 0.871.

ConclusionsUpregulated SLPI correlates with aggressive pathologic characteristics of colorectal cancer; SLPI could be used as an indicator of progression and metastasis in patients with colorectal cancer.

KeywordsColorectal cancer Immunohistochemistry Metastasis Prognosis Secretory leukocyte protease inhibitor AbbreviationsBSAbovine serum albumin

DAB3,3-diaminobenzidine

PBSphosphate buffered saline

PBT10× PBS, 10% BSA, 10% Triton X-100 in double distilled H2O

SLPIsecretory leukocyte protease inhibitor.

Electronic supplementary materialThe online version of this article doi:10.1186-1477-7819-12-369 contains supplementary material, which is available to authorized users.

Guiying Liu, Jingyan Yang contributed equally to this work.

Download fulltext PDF



Autor: Guiying Liu - Jingyan Yang - Yulei Zhao - Zhijing Wang - Baoheng Xing - Liang Wang - Dongliang Shi

Fuente: https://link.springer.com/







Documentos relacionados